7FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a combination of a co-drug (an auxiliary) and a compound o formula 
(IV) in which radicals and symbols have the values defined in cl. 1 of the patent claim, or salts, or tautomers, or N-oxides, or solvates of this compound; where the specified auxiliary is specified from a monoclonal antibody, an alkylating agent, a malignant growth agent, other cycline-dependent kinase (CDK) inhibitor and a hormone, a hormone agonist, a hormone antagonist or a hormone-modulating agent specified in cl. 1 of the patent claim. The offered combination is used for tumour cell growth inhibition.
EFFECT: invention also refers to a pharmaceutical composition based on the offered combination, application of the combination and its separate ingredients and methods of treating, preventing and relieving the cancer symptoms in a patient.
77 cl, 2 dwg, 8 tbl, 257 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS USED IN PHARMACEUTICS | 2006 |
|
RU2425677C2 |
| 3,4-SUBSTITUTED 1H-PIRAZOLE COMPOUNDS AND THEIR APPLICATION AS CYCLIN-DEPENDANT KINASES (CDK) AND MODULATORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | 2004 |
|
RU2408585C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
| COMBINATION THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR TREATMENT OF CANCER | 2016 |
|
RU2786570C2 |
| PHARMACEUTICAL COMPOUNDS | 2015 |
|
RU2687060C2 |
| 11β-HYDROXYSTEROID DIHYDROGENASE INHIBITORS | 2008 |
|
RU2440989C2 |
| 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | 2016 |
|
RU2736123C1 |
| COMPOUNDS FOR TREATING COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2703995C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2010 |
|
RU2577700C2 |
| DERIVATIVES OF 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE EFFECTIVE AS CB1 MODULATORS | 2005 |
|
RU2375349C2 |
